How progestins influence the cardiovascular effect of hormone replacement therapy

G. M C Rosano, G. Mercuro, C. Vitale, P. Rossini, P. Galetta, M. Fini

Research output: Contribution to journalArticle

Abstract

Hormone replacement therapy aims to protect against osteoporosis and alleviate fastidious menopausal symptoms such as hot flushes, depression, sleep disturbances and vaginal dryness. In view of the acknowledgement of estrogen deficiency as a major trigger for the acceleration of cardiovascular risk after menopause, hormone replacement therapy may also be proposed as a substantial beneficial cardioprotective agent. The effects of progestins on lipoprotein profile and vasomotor tone are dependent on the chemical structure and the scheme of administration of progestins, with androgenic progestins and cyclical therapy having a potential detrimental effect. Prospective primary and secondary prevention studies, however, suggest that the adjunct of non-androgenic progestins to estrogen therapy is at least as effective as estrogen replacement therapy in reducing cardiovascular mortality and morbidity. Data from recent randomized secondary prevention studies have to be viewed with caution.

Original languageEnglish
Pages (from-to)9-17
Number of pages9
JournalGynecological Endocrinology
Volume15
Issue numberSUPPL. 6
Publication statusPublished - 2001

Fingerprint

Hormone Replacement Therapy
Progestins
Secondary Prevention
Estrogens
Cardiotonic Agents
Estrogen Replacement Therapy
Primary Prevention
Menopause
Lipoproteins
Osteoporosis
Sleep
Depression
Morbidity
Mortality
Therapeutics

Keywords

  • Cardiovascular effects
  • Hormone replacement therapy
  • Progestins

ASJC Scopus subject areas

  • Endocrinology
  • Obstetrics and Gynaecology

Cite this

How progestins influence the cardiovascular effect of hormone replacement therapy. / Rosano, G. M C; Mercuro, G.; Vitale, C.; Rossini, P.; Galetta, P.; Fini, M.

In: Gynecological Endocrinology, Vol. 15, No. SUPPL. 6, 2001, p. 9-17.

Research output: Contribution to journalArticle

@article{e99d98b518e14de796f94e7b955933f2,
title = "How progestins influence the cardiovascular effect of hormone replacement therapy",
abstract = "Hormone replacement therapy aims to protect against osteoporosis and alleviate fastidious menopausal symptoms such as hot flushes, depression, sleep disturbances and vaginal dryness. In view of the acknowledgement of estrogen deficiency as a major trigger for the acceleration of cardiovascular risk after menopause, hormone replacement therapy may also be proposed as a substantial beneficial cardioprotective agent. The effects of progestins on lipoprotein profile and vasomotor tone are dependent on the chemical structure and the scheme of administration of progestins, with androgenic progestins and cyclical therapy having a potential detrimental effect. Prospective primary and secondary prevention studies, however, suggest that the adjunct of non-androgenic progestins to estrogen therapy is at least as effective as estrogen replacement therapy in reducing cardiovascular mortality and morbidity. Data from recent randomized secondary prevention studies have to be viewed with caution.",
keywords = "Cardiovascular effects, Hormone replacement therapy, Progestins",
author = "Rosano, {G. M C} and G. Mercuro and C. Vitale and P. Rossini and P. Galetta and M. Fini",
year = "2001",
language = "English",
volume = "15",
pages = "9--17",
journal = "Gynecological Endocrinology",
issn = "0951-3590",
publisher = "Informa Healthcare",
number = "SUPPL. 6",

}

TY - JOUR

T1 - How progestins influence the cardiovascular effect of hormone replacement therapy

AU - Rosano, G. M C

AU - Mercuro, G.

AU - Vitale, C.

AU - Rossini, P.

AU - Galetta, P.

AU - Fini, M.

PY - 2001

Y1 - 2001

N2 - Hormone replacement therapy aims to protect against osteoporosis and alleviate fastidious menopausal symptoms such as hot flushes, depression, sleep disturbances and vaginal dryness. In view of the acknowledgement of estrogen deficiency as a major trigger for the acceleration of cardiovascular risk after menopause, hormone replacement therapy may also be proposed as a substantial beneficial cardioprotective agent. The effects of progestins on lipoprotein profile and vasomotor tone are dependent on the chemical structure and the scheme of administration of progestins, with androgenic progestins and cyclical therapy having a potential detrimental effect. Prospective primary and secondary prevention studies, however, suggest that the adjunct of non-androgenic progestins to estrogen therapy is at least as effective as estrogen replacement therapy in reducing cardiovascular mortality and morbidity. Data from recent randomized secondary prevention studies have to be viewed with caution.

AB - Hormone replacement therapy aims to protect against osteoporosis and alleviate fastidious menopausal symptoms such as hot flushes, depression, sleep disturbances and vaginal dryness. In view of the acknowledgement of estrogen deficiency as a major trigger for the acceleration of cardiovascular risk after menopause, hormone replacement therapy may also be proposed as a substantial beneficial cardioprotective agent. The effects of progestins on lipoprotein profile and vasomotor tone are dependent on the chemical structure and the scheme of administration of progestins, with androgenic progestins and cyclical therapy having a potential detrimental effect. Prospective primary and secondary prevention studies, however, suggest that the adjunct of non-androgenic progestins to estrogen therapy is at least as effective as estrogen replacement therapy in reducing cardiovascular mortality and morbidity. Data from recent randomized secondary prevention studies have to be viewed with caution.

KW - Cardiovascular effects

KW - Hormone replacement therapy

KW - Progestins

UR - http://www.scopus.com/inward/record.url?scp=0344269924&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0344269924&partnerID=8YFLogxK

M3 - Article

C2 - 12227881

AN - SCOPUS:0344269924

VL - 15

SP - 9

EP - 17

JO - Gynecological Endocrinology

JF - Gynecological Endocrinology

SN - 0951-3590

IS - SUPPL. 6

ER -